Cargando…
Phase II Study of ENZAlutamide Combined With Hypofractionated Radiation Therapy (ENZART) for Localized Intermediate Risk Prostate Cancer
BACKGROUND: Intermediate-risk prostate cancer (PCa) is usually treated by a combination of external beam radiation therapy (EBRT) and a short course of androgen deprivation therapy (ADT). ADT is associated with multiple side effects, including weight gain, loss of libido, and hot flashes. In contras...
Autores principales: | Lara, Pedro C., Rodríguez-Melcón, Juan I., Palacios-Eito, Amalia, Lozano, Antonio, Hervás-Morón, Asunción, Villafranca, Elena, Gómez-Iturriaga, Alfonso, Sancho, Gemma, Maldonado, Xavier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329530/ https://www.ncbi.nlm.nih.gov/pubmed/35912190 http://dx.doi.org/10.3389/fonc.2022.891886 |
Ejemplares similares
-
Health-related quality of life in men with localized prostate cancer treated with radiotherapy: validation of an abbreviated version of the Expanded Prostate Cancer Index Composite for Clinical Practice in Spain
por: Zapatero, Almudena, et al.
Publicado: (2021) -
Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer
por: Ju, Andrew W, et al.
Publicado: (2013) -
Extreme Hypofractionation with SBRT in Localized Prostate Cancer
por: Gómez-Aparicio, Maria Antonia, et al.
Publicado: (2021) -
Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
por: Kim, Hun Jung, et al.
Publicado: (2016) -
Hypofractionated Radiotherapy in Intermediate-Risk Prostate Cancer Patients: Long-Term Results
por: Valeriani, Maurizio, et al.
Publicado: (2022)